Retraction Watch

Tracking retractions as a window into the scientific process

Archive for the ‘j clin oncology’ Category

Error in one line of code sinks cancer study

without comments

journl-of-clinical-oncologyAuthors of a 2016 cancer paper have retracted it after finding an error in one line of code in the program used to calculate some of the results.

Sarah Darby, last author of the now-retracted paper from the University of Oxford, UK, told Retraction Watch that the mistake was made by a doctoral student. When the error was realized, Darby said, she contacted the Journal of Clinical Oncology (JCO), explained the issue, and asked whether they would prefer a retraction or a correction. JCO wanted a retraction, and she complied.

The journal allowed the authors to publish a correspondence article outlining their new results.

Here’s the lengthy retraction notice, published online last month: Read the rest of this entry »

Oh no he didn’t! Misattributed Aristotle work leads to correction in highly cited cancer paper

with one comment

jcoJohn Shannon may be a mere undergrad at Hillsdale College in Michigan, but he knows enough about history to be surprised that Aristotle had written an entire book about economics that Shannon had never heard of.

That curiosity led to the discovery that a highly cited paper about pricing in cancer drugs was missing a reference to a rather relevant source about a treatise by the Greek philosopher, prompting the Journal of Clinical Oncology to correct the paper. But to Shannon, a missing reference is not the only problem with the paper.

As he notes in an essay in Public Discourse, Shannon’s interest was piqued when he noticed this passage in a 2013 paper in the Journal of Clinical Oncology on the fair price — “just price,” or Justum Pretium — of cancer drugs: Read the rest of this entry »

Duke’s Anil Potti resigns

without comments

Duke University photo

Duke’s Anil Potti, the Duke cancer researcher who falsely claimed to be a Rhodes Scholar and may have faked several analyses of chemotherapy and cancer, has resigned from the university.

The Duke Chronicle reports that Potti

…stepped down from his position at Duke’s Institute for Genome Sciences and Policy Friday and took responsibility for the problems in his research, IGSP Director Huntington Willard wrote in an e-mail to IGSP staff.

Willard wrote that Potti “accepted full responsibility for a series of anomalies in data handling, analysis and management that have come under scrutiny in the past months.”

He said that investigations into Potti’s research will continue, as will IGSP’s examinations of Potti’s science.

The resignation follows the retraction earlier this week of one paper Potti co-authored in the Journal of Clinical Oncology.

We’ll update as we learn more.

Please see an update about a second paper now being retracted by one of Potti’s co-authors.